结直肠癌与后续糖尿病风险:台湾一项基于人群的队列研究
该研究利用台湾癌症登记数据库(2007-2018)链接健康数据库,纳入86 268例结直肠癌患者及等量倾向评分匹配的普通人群,评估结直肠癌与后续糖尿病风险及化疗的影响。结直肠癌患者发生糖尿病的风险比匹配普通人群高14%(HR 1.14;95%CI 1.09-1.20),诊断后第一年风险最高,随后持续升高;3年内化疗超过180天与后续糖尿病风险增加60%至70%相关(HR 1.64;95%CI 1.07-2.49)。作者认为监测血糖对结直肠癌患者至关重要,尤其是长期化疗期间。
要点
- 结直肠癌患者糖尿病风险较匹配普通人群高14%(HR 1.14;95%CI 1.09-1.20)。
- 诊断后第一年糖尿病风险最高,随后持续升高。
- 3年内化疗超过180天与后续糖尿病风险增加60%至70%相关(HR 1.64;95%CI 1.07-2.49)。
核心结论
- 结直肠癌患者与糖尿病风险升高相关,长期化疗尤其涉及卡培他滨者增加糖尿病风险,因此监测血糖对结直肠癌患者至关重要,尤其是长期化疗期间。
研究设计与样本
- 这是一项全国性队列研究,使用台湾癌症登记数据库(2007-2018)并链接健康数据库。
- 纳入86 268例结直肠癌患者及等量倾向评分匹配的普通人群队列;其中37 277例来自台湾癌症登记(2007-2016)的结直肠癌患者用于分析化疗相关的糖尿病风险。
- 化疗暴露按诊断后3年内分为无化疗、<90天、90至180天、>180天四类,比较各类别的糖尿病风险差异。
主要发现
- 倾向评分匹配后每组各86 268名参与者。
- 结直肠癌患者发生糖尿病的风险比匹配普通人群高14%(HR 1.14;95%CI 1.09-1.20)。
- 诊断后第一年风险最高,随后风险持续升高。
- 3年内长期化疗(>180天)与后续糖尿病风险增加60%至70%相关(HR 1.64;95%CI 1.07-2.49)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The association between colorectal cancer (CRC) and new-onset diabetes mellitus remains unclear. OBJECTIVE: To examine the association between CRC and the risk of subsequent diabetes mellitus and to further investigate the impact of chemotherapy on diabetes mellitus risk in CRC. METHODS: In this nationwide cohort study using the Taiwan Cancer Registry database (2007-2018) linked with health databases, 86 268 patients with CRC and an equal propensity score-matched cohort from the general population were enrolled. Among them, 37 277 CRC patients from the Taiwan Cancer Registry (2007-2016) were analyzed for diabetes mellitus risk associated with chemotherapy. Chemotherapy exposure within 3 years of diagnosis was categorized as no chemotherapy, < 90 days, 90 to 180 days, and > 180 days. Differences in diabetes mellitus risk were assessed across these categories. RESULTS: Each group involved 86 268 participants after propensity score matching. The patients with CRC had a 14% higher risk of developing diabetes mellitus than the matched general population (hazard ratio [HR]: 1.14; 95% CI, 1.09-1.20). The highest risk was observed within the first year after diagnosis, followed by a sustained elevated risk. Long-term chemotherapy (> 180 days within 3 years) was associated with a 60% to 70% increased risk of subsequent diabetes mellitus (HR: 1.64; 95% CI, 1.07-2.49). CONCLUSION: Patients with CRC are associated with an elevated risk of diabetes mellitus, and long-term chemotherapy, particularly involving capecitabine, increases diabetes mellitus risk. Thus, monitoring blood glucose levels is crucial for patients with CRC, especially during extended chemotherapy.
引用
- Hsu HY, Chern YJ, Hsu MS, et al. Colorectal Cancer and Subsequent Diabetes Risk: A Population-Based Cohort Study in Taiwan. J Clin Endocrinol Metab. 2025. PMID: 38661006. doi:10.1210/clinem/dgae257
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。